Dr. Skarbnik on Future Combination Therapies With Tazemetostat in Follicular Lymphoma


Alan P. Z. Skarbnik, MD, discusses future combination therapies with tazemetostat in follicular lymphoma.

Alan P. Z. Skarbnik, MD, a hematologist/oncologist at Novant Health, discusses future combination therapies with tazemetostat (Tazverik) in follicular lymphoma.

Tazemetostat is a fairly well-tolerated treatment and has the potential to be combined with other therapies that are available, says Skarbnik. Typically in the drug development process, investigators will start with a well-tolerated single agent, which is then brought into earlier lines of therapy to see whether it can perform effectively when combined with other treatment regimens, according to Skarbnik.

Ongoing trials are examining tazemetostat plus chemoimmunotherapy for patients with relapsed follicular lymphoma. There appears to be a synergistic effect when tazemetostat is added to chemoimmunotherapy, although more data are needed to understand how this combination will be utilized and if it will be safe, says Skarbnik. More data are needed, but that is an exciting area of research, concludes Skarbnik.

Related Videos
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Rohan Garje, MD
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Samer A. Srour, MB ChB, MS
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences